| Type | Title | Author(s) | Year | Views |
| Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models | Ma, BBY; Lui, VWY; Hui, CWC; Lau, CPY; Wong, CH; Hui, EP; Ng, MHL; Cheng, SH; Tsao, SW; Tsang, C-M; Cheung, CSF; Ho, K; Chan, ATC | 2014 | 14 |
| |
| Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines | Ma, BBY; Lui, VWY; Hui, CWC; Lau, CPY; Wong, C-H; Hui, EP; Ng, MH; Tsao, SW; Li, Y; Chan, ATC | 2013 | 13 |
| |
| Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma | Chan, SL; Wong, C-H; Lau, CPY; Zhou, Q; Hui, CWC; Lui, VWY; Ma, BBY; Chan, ATC; Yeo, W | 2013 | 12 |
| |
| Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines | Ma, BBY; Lui, VWY; Cheung, CS; Lau, CPY; Ho, K; Hui, EP; Tsui, SKW; Ng, MH; Cheng, SH; Ng, PKS; Tsao, SW; Chan, ATC | 2013 | 29 |
| |
| Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma | Hui, EP; Lui, VWY; Wong, CSC; Ma, BBY; Lau, CPY; Cheung, CSF; Ho, K; Cheng, S-H; Ng, MHL; Chan, ATC | 2011 | 13 |
| |
| The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines | Ma, BBY; Lui, VWY; Hui, EP; Lau, CPY; Ho, K; Ng, MHL; Cheng, SH; Tsao, SW; Chan, ATC | 2010 | 334 |
| |
| Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response | Ma, BBY; Lui, VWY; Poon, FF; Wong, SCC; To, KF; Wong, E; Chen, H; Lo, KW; Tao, Q; Chan, ATC | 2010 | 536 |
| |
| Erratum: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response (Investigational New Drugs DOI: 10.1007/s10637-009-9316-7) | Ma, BBY; Lui, VWY; Poon, FF; Wong, SCC; To, KF; Wong, E; Chen, H; Lo, KW; Tao, Q; Ng, MHL; Cheng, SH; Chan, ATC | 2010 | 505 |
| |
| The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines | Ma, BBY; Sung, F; Tao, Q; Poon, FF; Lui, VW; Yeo, W; Chan, SL; Chan, ATC | 2010 | 14 |
| |
| STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro | Lui, VWY; Wong, EYL; Ho, Y; Hong, B; Wong, SCC; Tao, Q; Choi, GCG; Au, TCC; Ho, K; Yau, DMS; Ma, BBY; Hui, EP; Chan, ASK; Tsang, CM; Tsao, SW; Grandis, JR; Chan, ATC | 2009 | 280 |
| |
| Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas | Jin, H; Wang, X; Ying, J; Wong, AHY; Li, H; Lee, KY; Srivastava, G; Chan, ATC; Yeo, W; Ma, BBY; Putti, TC; Lung, ML; Shen, ZY; Xu, LY; Langford, C; Tao, Q | 2007 | 141 |
| |
| Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma | Sung, FL; Pang, RTK; Ma, BBY; Lee, MML; Shuk, MC; Poon, TCW; Chan, ATC | 2006 | 31 |
| |
